Skip to main content
Premium Trial:

Request an Annual Quote

Signal Genetics Regains Compliance With Nasdaq Listing Requirement

NEW YORK (GenomeWeb) – Signal Genetics said today that it has received a letter from Nasdaq notifying the company that it has regained compliance with the Nasdaq Capital Market's minimum bid price requirement for continued listing.

The letter noted that as of Nov. 21 the company evidenced a closing bid price of its common stock in excess of the $1 minimum requirement for at least 10 consecutive trading days.

Earlier this month Signal and Miragen Therapeutics announced their plans to merge, to divest Signal's molecular diagnostic assets, and to form a company fully focused on Miragen's microRNA therapeutics programs.

As part of the deal, which is expected to close in the first quarter of 2017, privately held Miragen will pick up Signal's Nasdaq listing.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more